CryoLife/Medafor
This article was originally published in The Gray Sheet
Executive Summary
CryoLife boosts its equity stake in privately held surgical hemostat maker Medafor to 11% through the purchase of 740,000 shares at $2 each, announced Feb. 2. Surgical adhesive maker CryoLife, which remains Medafor's largest shareholder, is seeking a negotiated acquisition of the rest of Medafor (1"The Gray Sheet" Jan. 18, 2010). While Medafor's board is weighing its options, CryoLife says it may seek a special shareholders meeting to replace the board
You may also be interested in...
CryoLife Takes Step To Wrest Control Of Reluctant Partner Medafor
CryoLife's purchase of an 8% equity stake in privately held surgical hemostat maker Medafor on Jan. 13 could be the first step of a hostile takeover
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.